---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-036122"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:42:15.484106+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q2 cash $60.3M; CRDF-004 readout expected 2H 2024

## Summary
- Cash and equivalents $60.3M as of June 30, 2024; runway to Q3 2025.
- Net cash used in ops $9.2M in Q2 2024 vs $7.1M in Q2 2023.
- Total operating expenses $12.7M for Q2 2024, up $0.4M YoY.
- CRDF-004 trial for first-line RAS-mutated mCRC data readout expected in 2H 2024.
- Preclinical data published on onvansertib + olaparib in olaparib-resistant ovarian cancer.

## SEC filing metadata
- accession: 0001628280-24-036122
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828024036122/0001628280-24-036122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828024036122/crdf-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-036122
- JSON: https://secwatch.observer/filing/0001628280-24-036122.json
- Plain text: https://secwatch.observer/filing/0001628280-24-036122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.